Comments
Dr Reddy's Laboratories has said there are no claims for monetary damages against the company in the unfavourable ruling in a US court with regard to anti-nausea injection.
In a statement filed with the BSE, Dr Reddy's said, “In this regard, we would like to state that there are no claims against the company for monetary damages because the proposed palonosetron product has not been marketed.”
As for quantum claims, it maintained the claims only sought injuctive relief against the company to prohibit the manufacturing, use, import and sale of the company's palonosetron product prior to expiration of the patents-in-suit. Therefore, Dr Reddy's stated it believes there is no monetary compensation or penalty damages owed to Helsinn due to this decision. The company issued this statement following a clarification sought about the company press statement issued on February 16, about Dr Reddy's announcement made on US district court's opinion relating to patent infringement.
The Hyderabad-based pharma major had informed the BSE it received an unfavourable ruling in a US court on a patent infringement matter over Aloxi.
The company had informed that a District Court in New Jersey, United States, issued its opinion regarding palonosetron product, pursuant to a paper NDA of the Food, Drug and Cosmetic Act.
It further stated that the Court found that Dr Reddy's proposed palonosetron hydrochloride 0.25 mg/5 ml product infringes certain claims of the US patents and that the certain asserted claims were not invalid.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.